jskn003
mAbexperimentalADC
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 2, 2022 (NCT05494918)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06998771 | Phase 2 | Jun 15, 2025 | Shanghai JMT-Bio Inc. |
| NCT06846437 | Phase 3 | Apr 30, 2025 | Fudan University, Shanghai JMT-Bio Inc. |
| NCT06751485 | Phase 3 | Jan 15, 2025 | Alphamab Co., Ltd. |
| NCT06079983 | Phase 3 | Dec 1, 2023 | Alphamab Co., Ltd., Fudan University, Sun Yat-Sen University |
| NCT05744427 | Phase 1/Phase 2 (Phase 2) | Mar 15, 2023 | Alphamab Co., Ltd., Peking University, Sun Yat-Sen University |
| NCT05494918 | Phase 1 | Sep 2, 2022 | Alphamab Co., Ltd., Breast Cancer Research Centre-WA,Hollywood Consulting Centre |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alphamab Co., Ltd. | For profit | 4 | 4 | 3 | 2022 |
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2023 |
| Shanghai JMT-Bio Inc. | For profit | 2 | 2 | 2 | 2025 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Breast Cancer Research Centre-WA,Hollywood Consulting Centre | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1